title: Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964.
abstract: This patent application claims a novel crystalline form (Form A) of a tosylate salt of a previously disclosed neutrophil elastase inhibitor. It also claims oral compositions of the salt and a process for the preparation of the crystalline form. The novel form is indicated to show improved physical properties relative to the free base. The claimed compound is evidently one of the elastase inhibitors currently being developed by AstraZeneca.
authors.affiliation: Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK petrosn@bigfoot.com
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000818:Animals; D003460:Crystallization; D006801:Humans; D010330:Patents as Topic; D053491:Proteinase Inhibitory Proteins, Secretory / Q000494:pharmacology* / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D011728:Pyridones / Q000494:pharmacology* / Q000627:therapeutic use; D013450:Sulfones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D053491:Proteinase Inhibitory Proteins, Secretory; D011728:Pyridones; D013450:Sulfones